Histologically confirmed nonsquamous NSCLC with activating EGFR mutation (on exon 19 deletion or exon 21 L858R mutation)
Stage IIIb, IV or recurrent NSCLC (AJCC 7th criteria)
Age ≥ 20 years
ECOG performance status of 0 or 1
At least one measurable lesion by RECIST 1.1
Progression after first line treatment with EGFR TKIs for advanced NSCLC
Asymptomatic brain metastasis or symptomatic brain metastasis treated with local treatment such as operation, whole brain radiotherapy, or gamma-knife surgery
At least 2 weeks later after whole brain radiotherapy or palliative radiotherapy
Organ function as evidenced by the following; Absolute neutrophil count \> 1.5 x 109/L; platelets \> 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT \< 3 UNL, in case of known hepatic metastasis, AST/ALT\< 5 UNL
Written informed consent form
No other previous systemic chemotherapy
You may not be if
Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia
Patients with post-obstructive pneumonia or uncontrolled serious infection
Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method)
Uncontrolled symptomatic brain metastasis
Presence of third space fluid which cannot be controlled by drainage
Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer.
